Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Dec;8(12):1501-3.
doi: 10.3201/eid0812.020115.

Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA,1982-2001

Irving Nachamkin  1 , Huong Ung, Ming Li
Affiliations

Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA,1982-2001

Irving Nachamkin et al. Emerg Infect Dis. 2002 Dec.

Abstract

Fluoroquinolone-resistant Campylobacter jejuni has been observed worldwide and is now being seen in the United States. Among patients in our health-care system in Pennsylvania, fluoroquinolone-resistant C. jejuni were not observed from 1982 to 1992; however, resistance increased to 40.5% in 2001. Resistance to erythromycin remains at a low level (<5%).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in erythromycin and ciprofloxacin resistance in Campylobacter jejuni, Philadelphia, 1982–2001. Number of isolates tested: 1982–92 (n=142), 1995 (n=24), 1996 (n=48), 1997 (n=61), 1998 (n=37), 1999 (n=22), 2000 (n=48), and 2001 (n=47).
Figure 2
Figure 2
Fluoroquinolone-resistant Campylobacter, by quarter, 2000–2001. Number of isolates tested for each quarter: Q1: 13, Q2: 13, Q3: 22, Q4: 10, Q5: 16, Q6: 15, Q7: 12, Q8: 14.
Figure 3
Figure 3
Distribution of ciprofloxacin MICs in Campylobacter jejuni, 1995–2001.
See this image and copyright information in PMC

References

    1. Friedman CR, Neimann J, Wegener HG, Tauxe RV. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, editors. Campylobacter. Washington: ASM Press; 2000. p. 121–39.
    1. Adachi JA, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antimicrobial therapy for traveler's diarrhea. Clin Infect Dis. 2000;31:1079–83. 10.1086/318119 - DOI - PubMed
    1. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001;7:24–34. - PMC - PubMed
    1. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. N Engl J Med. 1999;340:1525–32. 10.1056/NEJM199905203402001 - DOI - PubMed
    1. Centers for Disease Control and Prevention. National antimicrobial resistance monitoring system: enteric bacteria 2000 annual report. NARMS. Atlanta: The Centers; 2000.

MeSH terms

LinkOut - more resources